Clinic business

Scancell acquires Vacitech technology to advance Modi-2 to the clinic

Oxford-based Scancell Holdings, which develops novel immunotherapies, has licensed SNAPvax™ technology from Vaccitech plc, another Oxford biopharmaceutical company developing vaccines, and the team behind the Oxford AstraZeneca vaccine.

This agreement will allow Scancell to formulate and manufacture Modi-2, with the aim of initiating a Phase 1 clinical study in cancer patients in 2024.

Modi-2 is the second product in Scancell’s Moditope platform, which harnesses the immune system to target a unique class of post-translational modifications (PTMs) upregulated by many cancers. SNAPvax™ technology enables peptides to self-assemble with the potent adjuvant TLR-7/8a to promote strong T-cell responses and has been shown to successfully overcome formulation challenges associated with antigens immunogenic peptides, which are often highly hydrophobic and subject to manufacturing challenges with conventional formulations.

Professor Lindy Durrant, President and CEO of Scancell, said: “We are delighted to partner with Vaccitech to move the second candidate of our Moditope platform into GMP and further clinical development. With its elegant and efficient solution, the SNAPvax™ technology provides an excellent method of formulating the Modi-2 vaccine. Combining this technology with our expertise will allow us to develop a rapid manufacturing process for Modi-2, with the expectation that we can enter it into a Phase 1 clinical study in 2024.”

Dr. Geoffrey Lynn, Senior Vice President Synthetic Platforms at Vaccitech, said: “We are delighted that Scancell has chosen our SNAPvax™ technology for the development of their Modi-2 product. SNAPvax™ was developed to overcome the challenges of PTM formulation and delivery and ensure consistent formulations of all peptide antigens, for reliable T cell priming. Our team therefore wishes to support the development of this promising product in the hope it meets the immediate needs of cancer patients and more broadly underlines the promise of targeting TMDs.